AIM ImmunoTech Inc.

Name: AIM ImmunoTech Inc. standardized financial statements, quarterly
Creator: Listed

AIMNYSECIK 946644HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$26.0k, Q2 FY2026

Operating income−$3.5m, Q2 FY2026

Net income−$3.8m, Q2 FY2026

AIM ImmunoTech Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	2.7	3.2	2.0	1.1	1.4	1.7	1.1	1.2	0.6	1.1	0.5	0.6
Operating income	$m	(8.2)	(14.0)	(5.7)	(3.7)	(4.5)	(5.9)	(3.6)	(2.6)	(2.4)	(3.0)	(2.2)	(3.5)
Interest expense	$m	not reported	not reported	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.4	0.3	0.3
Net income	$m	(7.8)	(12.6)	(5.8)	(1.8)	(3.7)	(6.0)	(3.7)	(2.8)	(3.3)	(4.2)	(3.0)	(3.8)
Diluted EPS	$ per share	(0.16)	not reported	(0.12)	(3.00)	(6.00)	not reported	(0.05)	(3.68)	1.57	not reported	(0.69)	(0.43)
Basic EPS	$ per share	(0.16)	not reported	(0.12)	(3.00)	(6.00)	not reported	(0.05)	(3.68)	1.57	not reported	(0.69)	(0.43)

Balance sheet

Cash and equivalents$9.9m, Q2 FY2026

Long-term debt$3.6m, Q2 FY2026

Shareholders' equity$7.7m, Q2 FY2026

AIM ImmunoTech Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	period not labelled2024-12-11	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	5.4	3.3	3.6	0.9	not reported	1.7	0.9	0.5	2.3	3.0	5.8	9.9
Current assets	$m	14.6	11.3	10.4	7.6	not reported	4.2	2.6	1.0	2.6	3.3	6.2	10.4
Total assets	$m	19.4	16.2	15.7	13.6	not reported	8.6	6.2	4.1	5.5	5.8	8.6	12.7
Current liabilities	$m	8.7	9.9	8.8	10.1	not reported	9.5	9.8	10.4	4.0	6.2	6.1	4.9
Total liabilities	$m	9.1	11.4	9.6	10.7	not reported	9.9	10.1	10.7	11.6	15.6	6.5	5.0
Long-term debt	$m	not reported	1.0	0.3	0.1	not reported	2.8	2.4	2.7	not reported	0.9	0.2	3.6
Current portion of debt	$m	not reported	1.6	2.4	2.6	not reported	2.3	2.0	2.3	1.9	3.5	4.0	3.6
Shareholders' equity	$m	10.2	4.8	6.1	2.9	6.0	(1.3)	(3.9)	(6.5)	(6.1)	(9.8)	2.1	7.7

Cash flow

Operating cash flow−$4.6m, Q2 FY2026

Capital expenditure$0, Q4 FY2024

AIM ImmunoTech Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(5,671)	(9,758)	(4,815)	(3,008)	(3,110)	(3,955)	(2,361)	(1,531)	(5,079)	(1,986)	(2,719)	(4,590)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)17.12m, Q2 FY2026

AIM ImmunoTech Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	48.1	48.4	48.4	48.6	49.5	0.5	0.6	0.7	0.8	2.1	4.4	17.1

Shares outstanding: 30.44m at Aug 7, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. Listed shows no prices and gives no investment advice.